Zammar Ghassan, Cheah Chan Y
Department of Haematology, Sir Charles Gairdner Hospital, Perth, Western Australia, Australia.
Medical School, University of Western Australia, Perth, Western Australia, Australia.
Br J Haematol. 2025 Mar;206(3):1018-1019. doi: 10.1111/bjh.19949. Epub 2024 Dec 18.
Health-related quality of life measures are underemphasised in clinical trials and particularly valuable in follicular lymphoma as some interventions can result in substantial toxicity with uncertain impact on overall survival. The report by Marzolini and colleagues provides a nuanced discussion on the merits of rituximab monotherapy versus observation in asymptomatic follicular lymphoma patients. Commentary on: Marzolini et al. Quality of life in advanced-stage, asymptomatic, non-bulky follicular lymphoma treated with rituximab shows significant improvement compared with watchful-waiting. Br J Haematol 2025; 206:876-886.
与健康相关的生活质量指标在临床试验中未得到充分重视，而在滤泡性淋巴瘤中尤为重要，因为一些干预措施可能会导致严重毒性，且对总生存期的影响尚不确定。马尔佐利尼及其同事的报告对无症状滤泡性淋巴瘤患者使用利妥昔单抗单药治疗与观察等待的优缺点进行了细致入微的讨论。评论：马尔佐利尼等人。与观察等待相比，利妥昔单抗治疗晚期、无症状、非大包块滤泡性淋巴瘤患者的生活质量有显著改善。《英国血液学杂志》2025年；206:876 - 886。
